The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Camouflage strategies for therapeutic exosomes evasion from phagocytosis
Open accessAbstract
Background: Even though exosome-based therapy has been shown to be able to control the progression of different pathologies, the data revealed by pharmacokinetic studies warn of the low residence time of exogenous exosomes in circulation that can hinder the clinical translation of therapeutic exosomes. The macrophages related to the organs of the mononuclear phagocytic system are responsible primarily for the rapid clearance and retention of exosomes, which strongly limits the amount of exosomal particles available to reach the target tissue, accumulate in it and release with high efficiency its therapeutic cargo in acceptor target cells to exert the desired biological effect. Aim of review: Endowing exosomes with surface modifications to evade the immune system is a plausible strategy to contribute to the suppression of exosomal clearance and increase the efficiency of their targeted content delivery. Here, we summarize the current evidence about the mechanisms underlying the recognition and sequestration of therapeutic exosomes by phagocytic cells. Also, we propose different strategies to generate 'invisible' exosomes for the immune system, through the incorporation of different anti-phagocytic molecules on the exosomes' surface that allow increasing the circulating half-life of therapeutic exosomes with the purpose to increase their bioavailability to reach the target tissue, transfer their therapeutic molecular cargo and improve their efficacy profile. Key scientific concepts of review: Macrophage-mediated phagocytosis are the main responsible behind the short half-life in circulation of systemically injected exosomes, hindering their therapeutic effect. Exosomes 'Camouflage Cloak' strategy using antiphagocytic molecules can contribute to the inhibition of exosomal clearance, hence, increasing the on-target effect. Some candidate molecules that could exert an antiphagocytic role are CD47, CD24, CD44, CD31, β2M, PD-L1, App1, and DHMEQ. Pre- and post-isolation methods for exosome engineering are compatible with the loading of therapeutic cargo and the expression of antiphagocytic surface molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 3×
“First discovered in T cell, PD-1 is expressed by a variety of hematopoietic cells like B, NK, dendritic cells and macrophages [24,88,90], and is considered an immune checkpointmolecule that plays an important role in downregulating the immune system proinflammatory activity [90].”
BackgroundTumour exosome integrins determine organotropic metastasis
Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. (2015) · Nature · doi:10.1038/nature15756 · Cited by 5,101 · cited 3×
“In a context of cancer metastasis, the exosomal integrin’s profile strongly impacts in the pharmacokinetics of exosomes, determining their organotrophic behavior since there exist an intrinsic relation between integrins and the organotropism [15,54].”
BackgroundDelivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 1×
“Rabies virus glycoprotein (RVG) fused on the exosomes membrane has also been used to target the brain [14,52] and achieve a significant increase in brain accumulation measured by fluorescence [14].”
MethodPEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817 · cited 1×
“First discovered in T cell, PD-1 is expressed by a variety of hematopoietic cells like B, NK, dendritic cells and macrophages [24,88,90], and is considered an immune checkpointmolecule that plays an important role in downregulating the immune system proinflammatory activity [90].”
Background
Cited by
Exosome engineering in cell therapy and drug delivery
Sadeghi, S., Tehrani, F. R., Tahmasebi, S., Shafiee, A., & Hashemi, S. M. (2023) · Inflammopharmacology · doi:10.1007/s10787-022-01115-7 · Cited by 351
Exosome-Based Drug Delivery: Translation from Bench to Clinic
Koh, H. B., Kim, H. J., Kang, S.-W., & Yoo, T.-H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082042 · Cited by 259
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 252
Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review
Chen, Z., Xiong, M., Tian, J., Song, D., Duan, S., & Zhang, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02259-6 · Cited by 163
Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy
Lin, Y., Yan, M., Bai, Z., Xie, Y., Ren, L., Wei, J., Zhu, D., Wang, H., Liu, Y., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01636-x · Cited by 125
“However, the clearance rate of exogenous exosomes after systemic injection showed no differences from that of liposomes due to poor targeting of unmodified exosomes, which are mainly taken up by the mononuclear phagocyte system [20, 37].”
Background
Metadata
- Authors
- Parada, N., Romero-Trujillo, A., Georges, N., & Alcayaga-Miranda, F.
- Venue
- Journal of Advanced Research
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 31
- Pages
- 61-74
- ISSN
- 2090-1224 (ISSN-L)
- 2090-1232
- OpenAlex
- W3120723885
- Cited by
- 230
- References
- 18
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Camouflage strategies for therapeutic exosomes evasion from phagocytosis. https://app.cochat.ai/papers/10.1016/j.jare.2021.01.001
- The paper
- Parada, N., Romero-Trujillo, A., Georges, N., & Alcayaga-Miranda, F. (2021). Camouflage strategies for therapeutic exosomes evasion from phagocytosis. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2021.01.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.